Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

FRIDAY, May 16, 2025 (HealthDay News) — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to ...

Synthego, a Bay Area biotech startup that won hundreds of millions of dollars in funding for its gene editing products and ...

The clinical-stage biotech company is based in Sacramento, and is putting its drug candidate through medical trials.

The Beachwood-based company announced on Tuesday, May 20, that it has appointed Dr. David Llewellyn as its new CEO and as a ...

Tucked away on the north edge of Jacksonville, surrounded by farm fields, sits a large facility where a small team assembles ...

Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...